Eli Lilly (NYSE:LLY) has decided to end its partnership with CVS Health (NYSE:CVS) as the pharmacy benefits provider for its U.S. employees, following CVS’s decision to drop coverage of Lilly’s weight-loss medication in favor of a rival treatment from Novo Nordisk (NYSE:NVO), Bloomberg News reported Tuesday.

According to documents reviewed by Bloomberg, the change will take effect on January 1, when employees enrolled in Lilly’s medical plan will be automatically switched to coverage managed by Rightway, a different pharmacy benefits manager.

The move follows CVS’s choice to exclude Eli Lilly’s weight-loss drug from its formulary while maintaining coverage for Novo Nordisk’s competing product — a decision that reportedly prompted Lilly to seek an alternative provider for its workforce.

Eli Lilly stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.